A 24-Week, International, Multi Centre, Randomised, Double-Blind, Double-Dummy, Parallel Group, Phase IV Clinical Trial Investigating Changes in Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) Treated With Either 100 microg PTH(1-84) Daily or 70 mg Alendronate Weekly.

Trial Profile

A 24-Week, International, Multi Centre, Randomised, Double-Blind, Double-Dummy, Parallel Group, Phase IV Clinical Trial Investigating Changes in Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) Treated With Either 100 microg PTH(1-84) Daily or 70 mg Alendronate Weekly.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Alendronic acid; Parathyroid hormone
  • Indications Back pain; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms RELIEF
  • Sponsors Takeda Pharmaceuticals International GmbH
  • Most Recent Events

    • 07 May 2012 Company (Takeda Global Research and Development Center) added as reported by ClinicalTrials.gov.
    • 13 Aug 2010 Planned end date changed from 1 Dec 2011 to 1 Sep 2010 as reported by ClinicalTrials.gov.
    • 13 Aug 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top